AOP 03-007 - ANAHYDRET Study A single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia
Main Overview Study Protocol Appendix I Activity Sheet Contact	AOP 03-007 – ANAHYDRET STUDY A single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia Sponsor: AOP Orphan Pharmaceuticals AG, Wilheminenstr.91/II f/B4,A-1160 Vienna - AUSTRIA Tel: +43 / 1- 503 72 44; Fax: +43 / 1- 503 72 44-5 Overview: Study Protocol - Inclusion criteria - Exclusion criteria - Randomisation/Patient number allocation - Study Activities - Administration of Study Drug - Duration of study Appendix I - Diagnostic Criteria: Essential Thrombocythaemia - High risk profile Activity Sheet For further information please see the Contact Information for your country.